β Scribed by Maria Valeria Corrias; Paola Scaruffi; Marzia Occhino; Bruno De Bernardi; Gian Paolo Tonini; Vito Pistoia
No coin nor oath required. For personal study only.
The human MAGE-I, MAGEJ and MART-I genes code for antigens that are specifically recognized by cytolytic T lymphocytes in a MHC-restricted manner. The MAGE-I and MAGEJ genes are expressed in tumors of different histotypes but not in normal adult tissues (with the exception of testis), while the MART-I gene appears to be selectively expressed in melanoma. MAGE-I, MAGEJ and MART-I antigens may therefore constitute useful targets for specific anti-tumor immunization of cancer patients. Here we have investigated the expression of MAGE-I, MAGE-3 and MART-I in I I neuroblastoma (NB) cell lines and 73 NB tumor masses. MAGE-I and MAGE-3 transcripts were detected simultaneously in 36% of the cell lines and in 16% of tumor samples. The MAGE-I gene was never expressed alone except in one tumor. In contrast, MAGEJ mRNA was found in approximately 40% of the NB tumor samples in the absence of MAGE-I mRNA. No expression of the MART-I gene was observed in any cell line or tumor sample. No correlation was found between MAGE gene expression and clinical stage, event-free survival and presence or absence of N-myc amplification.
π SIMILAR VOLUMES
ized in a human melanoma cell line (MZ2-MEL). 4 Expression The MAGE-1 gene, originally isolated from a human of the MAGE-1 gene on HLA-A1 positive tumor cells directs melanoma cell line, directs the expression of a potential the expression of a nonapeptide that allows specific recognitumor-rejection
Human genes MAGE-I and MAGE-3 code for antigens that are recognized on melanoma cells by autologous cytolytic T lymphocytes. These antigens may constitute useful targets for specific anti-tumor immunization of cancer patients, since genes MAGE-I and MACE-3 are expressed in a number of tumors of diff
## Abstract ## Background. Certain tumor antigens have been identified that stimulate an immune response, thus making them targets for immunotherapy. NYβESOβ1, MAGEβ1, and MAGEβ3 are such antigens. This study was undertaken to determine their presence or absence in head and neck squamous cell canc